{"id":"https://openalex.org/W2012425798","doi":"https://doi.org/10.2147/dmso.s58786","title":"Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet","display_name":"Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet","publication_year":2014,"publication_date":"2014-07-01","ids":{"openalex":"https://openalex.org/W2012425798","doi":"https://doi.org/10.2147/dmso.s58786","mag":"2012425798","pmid":"https://pubmed.ncbi.nlm.nih.gov/25061325","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4085306"},"language":"en","primary_location":{"id":"doi:10.2147/dmso.s58786","doi":"https://doi.org/10.2147/dmso.s58786","is_oa":true,"landing_page_url":"https://doi.org/10.2147/dmso.s58786","pdf_url":"https://www.dovepress.com/getfile.php?fileID=20659","source":{"id":"https://openalex.org/S176615914","display_name":"Diabetes Metabolic Syndrome and Obesity","issn_l":"1178-7007","issn":["1178-7007"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-100","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.dovepress.com/getfile.php?fileID=20659","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5112909290","display_name":"Steve P. Vickers","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210092330","display_name":"RenaSci (United Kingdom)","ror":"https://ror.org/00e2dwm47","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210092330"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Steven P Vickers","raw_affiliation_strings":["RenaSci, BioCity Nottingham, Nottingham, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"RenaSci, BioCity Nottingham, Nottingham, UK","institution_ids":["https://openalex.org/I4210092330"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018284364","display_name":"Sharon C. Cheetham","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210092330","display_name":"RenaSci (United Kingdom)","ror":"https://ror.org/00e2dwm47","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210092330"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Sharon Cheetham","raw_affiliation_strings":["RenaSci, BioCity Nottingham, Nottingham, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"RenaSci, BioCity Nottingham, Nottingham, UK","institution_ids":["https://openalex.org/I4210092330"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018360944","display_name":"Katie R. Headland","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210092330","display_name":"RenaSci (United Kingdom)","ror":"https://ror.org/00e2dwm47","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210092330"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Katie Headland","raw_affiliation_strings":["RenaSci, BioCity Nottingham, Nottingham, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"RenaSci, BioCity Nottingham, Nottingham, UK","institution_ids":["https://openalex.org/I4210092330"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112253933","display_name":"Keith Dickinson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210092330","display_name":"RenaSci (United Kingdom)","ror":"https://ror.org/00e2dwm47","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210092330"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Keith Dickinson","raw_affiliation_strings":["RenaSci, BioCity Nottingham, Nottingham, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"RenaSci, BioCity Nottingham, Nottingham, UK","institution_ids":["https://openalex.org/I4210092330"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082492698","display_name":"Rolf Grempler","orcid":"https://orcid.org/0000-0002-9291-4947","observed_orcids":["https://orcid.org/0000-0002-9291-4947"]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Rolf Grempler","raw_affiliation_strings":["Boehringer Ingelheim Pharma, Biberach an der Riss, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharma, Biberach an der Riss, Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073470602","display_name":"Eric Mayoux","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":true,"raw_author_name":"Eric Mayoux","raw_affiliation_strings":["Boehringer Ingelheim Pharma, Biberach an der Riss, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharma, Biberach an der Riss, Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101439694","display_name":"Michael Mark","orcid":"https://orcid.org/0000-0002-8284-5773","observed_orcids":["https://orcid.org/0000-0002-8284-5773"]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Michael Mark","raw_affiliation_strings":["Boehringer Ingelheim Pharma, Biberach an der Riss, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharma, Biberach an der Riss, Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5032965517","display_name":"Thomas Klein","orcid":"https://orcid.org/0000-0001-5762-9166","observed_orcids":["https://orcid.org/0000-0001-5762-9166"]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Thomas Klein","raw_affiliation_strings":["Boehringer Ingelheim Pharma, Biberach an der Riss, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharma, Biberach an der Riss, Germany","institution_ids":["https://openalex.org/I1330995197"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5073470602"],"corresponding_institution_ids":["https://openalex.org/I1330995197"],"apc_list":{"value":2836,"currency":"USD","value_usd":2836},"apc_paid":{"value":2836,"currency":"USD","value_usd":2836},"fwci":3.7517,"has_fulltext":true,"cited_by_count":62,"citation_normalized_percentile":{"value":0.92382121,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"7","issue":null,"first_page":"265","last_page":"265"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.9678000211715698,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.9678000211715698,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.02930000051856041,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10489","display_name":"Regulation of Appetite and Obesity","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2807","display_name":"Endocrine and Autonomic Systems"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/empagliflozin","display_name":"empagliflozin","score":1.0},{"id":"https://openalex.org/keywords/sglt2-inhibitors","display_name":"SGLT2 inhibitors","score":0.8960000276565552},{"id":"https://openalex.org/keywords/orlistat","display_name":"orlistat","score":0.9929999709129333},{"id":"https://openalex.org/keywords/sibutramine","display_name":"sibutramine","score":1.0},{"id":"https://openalex.org/keywords/obesity","display_name":"obesity","score":0.7059999704360962},{"id":"https://openalex.org/keywords/cafeteria-diet","display_name":"cafeteria diet","score":0.7820000052452087},{"id":"https://openalex.org/keywords/weight-loss","display_name":"weight loss","score":0.7649999856948853},{"id":"https://openalex.org/keywords/glucose-tolerance","display_name":"glucose tolerance","score":0.7160000205039978},{"id":"https://openalex.org/keywords/leptin","display_name":"leptin","score":0.8059999942779541},{"id":"https://openalex.org/keywords/insulin","display_name":"insulin","score":0.7250000238418579},{"id":"https://openalex.org/keywords/body-fat","display_name":"fat mass","score":0.7599999904632568},{"id":"https://openalex.org/keywords/urinary-glucose-excretion","display_name":"urinary glucose excretion","score":0.8029999732971191},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7369999885559082},{"id":"https://openalex.org/keywords/prediabetes","display_name":"prediabetes","score":0.8479999899864197},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":1.0}],"concepts":[{"id":"https://openalex.org/C2780780548","wikidata":"https://www.wikidata.org/wiki/Q424163","display_name":"Orlistat","level":4,"score":0.9719919562339783},{"id":"https://openalex.org/C2775887513","wikidata":"https://www.wikidata.org/wiki/Q5373824","display_name":"Empagliflozin","level":4,"score":0.9703919887542725},{"id":"https://openalex.org/C2777646958","wikidata":"https://www.wikidata.org/wiki/Q424151","display_name":"Sibutramine","level":4,"score":0.9071205854415894},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.6381815075874329},{"id":"https://openalex.org/C2780509477","wikidata":"https://www.wikidata.org/wiki/Q267","display_name":"Cafeteria","level":2,"score":0.6205591559410095},{"id":"https://openalex.org/C544821477","wikidata":"https://www.wikidata.org/wiki/Q718113","display_name":"Weight loss","level":3,"score":0.5882235765457153},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5556452870368958},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5381276607513428},{"id":"https://openalex.org/C2780473172","wikidata":"https://www.wikidata.org/wiki/Q5572518","display_name":"Glycemic","level":3,"score":0.5116401314735413},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.5051367878913879},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4116198420524597},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.3943818211555481},{"id":"https://openalex.org/C511355011","wikidata":"https://www.wikidata.org/wiki/Q12174","display_name":"Obesity","level":2,"score":0.3752777576446533},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.37306779623031616},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[],"locations_count":6,"locations":[{"id":"doi:10.2147/dmso.s58786","doi":"https://doi.org/10.2147/dmso.s58786","is_oa":true,"landing_page_url":"https://doi.org/10.2147/dmso.s58786","pdf_url":"https://www.dovepress.com/getfile.php?fileID=20659","source":{"id":"https://openalex.org/S176615914","display_name":"Diabetes Metabolic Syndrome and Obesity","issn_l":"1178-7007","issn":["1178-7007"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-100","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:3077071","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4085306","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:4085306","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4085306","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Metab Syndr Obes","raw_type":"Text"},{"id":"pmid:25061325","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25061325","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, metabolic syndrome and obesity : targets and therapy","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:7b3c800174874f538ad970f2bff883fa","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/7b3c800174874f538ad970f2bff883fa","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Diabetes, Metabolic Syndrome and Obesity, Vol 2014, Iss default, Pp 265-275 (2014)","raw_type":"article"},{"id":"pmh:oai:dovepress.com/17427","doi":null,"is_oa":true,"landing_page_url":"https://www.dovepress.com/combination-of-the-sodium-glucose-cotransporter-2-inhibitor-empagliflo-peer-reviewed-article-DMSO","pdf_url":null,"source":{"id":"https://openalex.org/S4306401012","display_name":"Dove Medical Press (Taylor and Francis Group)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.2147/dmso.s58786","doi":"https://doi.org/10.2147/dmso.s58786","is_oa":true,"landing_page_url":"https://doi.org/10.2147/dmso.s58786","pdf_url":"https://www.dovepress.com/getfile.php?fileID=20659","source":{"id":"https://openalex.org/S176615914","display_name":"Diabetes Metabolic Syndrome and Obesity","issn_l":"1178-7007","issn":["1178-7007"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-100","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9922999739646912}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2012425798.pdf","grobid_xml":"https://content.openalex.org/works/W2012425798.grobid-xml"},"referenced_works_count":35,"referenced_works":["https://openalex.org/W1504089656","https://openalex.org/W1985359885","https://openalex.org/W1997746154","https://openalex.org/W1999227300","https://openalex.org/W2013623792","https://openalex.org/W2015327820","https://openalex.org/W2022514673","https://openalex.org/W2038961968","https://openalex.org/W2045452864","https://openalex.org/W2051243940","https://openalex.org/W2061997489","https://openalex.org/W2080424087","https://openalex.org/W2080449229","https://openalex.org/W2080672477","https://openalex.org/W2098289172","https://openalex.org/W2107028927","https://openalex.org/W2115926243","https://openalex.org/W2119779723","https://openalex.org/W2119981294","https://openalex.org/W2120678647","https://openalex.org/W2134855422","https://openalex.org/W2134860420","https://openalex.org/W2139530732","https://openalex.org/W2144173715","https://openalex.org/W2150855258","https://openalex.org/W2162780634","https://openalex.org/W2164231447","https://openalex.org/W2164467222","https://openalex.org/W2167245776","https://openalex.org/W2168647804","https://openalex.org/W2171183320","https://openalex.org/W2171471305","https://openalex.org/W2313669804","https://openalex.org/W3206033760","https://openalex.org/W4243842508"],"related_works":["https://openalex.org/W3171629882","https://openalex.org/W7117654225","https://openalex.org/W2609557735","https://openalex.org/W3080961876","https://openalex.org/W4321601736","https://openalex.org/W2911721172","https://openalex.org/W7137477628","https://openalex.org/W2956936609","https://openalex.org/W4385478736","https://openalex.org/W4311662008"],"abstract_inverted_index":{"The":[0,91,122,153],"present":[1],"study":[2],"assessed":[3],"the":[4,7,25,208,229],"potential":[5],"of":[6,93,124,155,213,231],"sodium":[8],"glucose-linked":[9],"transporter":[10],"(SGLT)-2":[11],"inhibitor":[12],"empagliflozin":[13,73,125,171,194,205],"to":[14,45,49,133,150,157,176,217],"decrease":[15],"body":[16,110,115,130,196],"weight":[17,131,197],"when":[18],"administered":[19],"alone":[20],"or":[21,80,210,219,236],"in":[22,33,161,179,198,215],"combination":[23,123,173,203],"with":[24,77,136,170,186,234],"clinically":[26],"effective":[27],"weight-loss":[28],"agents":[29],"orlistat":[30,127,218],"and":[31,59,85,102,114,126,140,147,172],"sibutramine":[32,79,156,220],"obese":[34,200,232],"rats":[35,42],"fed":[36],"a":[37,46,71,177],"cafeteria":[38,47],"diet.":[39],"Female":[40],"Wistar":[41],"were":[43,67,88],"exposed":[44],"diet":[48],"induce":[50],"obesity.":[51],"Empagliflozin":[52,107],"was":[53,105,166],"dosed":[54],"once":[55],"daily":[56],"(10,":[57],"30,":[58],"60":[60],"mg/kg)":[61,76],"for":[62,228],"28":[63],"days.":[64],"Combination":[65],"studies":[66,223],"subsequently":[68],"performed":[69],"using":[70],"submaximal":[72],"dose":[74],"(10":[75],"either":[78,137,187],"orlistat.":[81],"Body":[82],"weight,":[83,111],"food,":[84],"water":[86],"intake":[87],"recorded":[89],"daily.":[90],"effect":[92,154],"drug":[94,138,188],"treatment":[95,174,230],"on":[96],"glucose":[97,120,143],"tolerance,":[98,144],"relevant":[99],"plasma":[100,112,145],"parameters,":[101],"carcass":[103,180],"composition":[104],"determined.":[106],"dose-dependently":[108],"reduced":[109,129],"leptin,":[113],"fat":[116,181],"though":[117],"increased":[118],"urinary":[119],"excretion.":[121],"significantly":[128,141,168],"compared":[132,149],"animals":[134,214],"treated":[135],"alone,":[139],"improved":[142,207,226],"insulin,":[146],"leptin":[148],"vehicle-treated":[151],"controls.":[152],"improve":[158],"glycemic":[159],"control":[160],"an":[162],"oral":[163],"glucose-tolerance":[164],"test":[165],"also":[167],"increased,":[169],"leading":[175],"reduction":[178],"greater":[182],"than":[183],"that":[184,193],"observed":[185],"alone.":[189,221],"These":[190],"data":[191],"demonstrate":[192],"reduces":[195],"cafeteria-fed":[199],"rats.":[201],"In":[202],"studies,":[204],"further":[206],"body-weight":[209],"body-fat":[211],"loss":[212],"comparison":[216],"Such":[222],"may":[224],"indicate":[225],"strategies":[227],"patients":[233],"prediabetes":[235],"type":[237],"2":[238],"diabetes.":[239]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":8},{"year":2021,"cited_by_count":9},{"year":2020,"cited_by_count":6},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":7},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":7},{"year":2015,"cited_by_count":5},{"year":2014,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}